ALX Oncology Holdings ALXO 深 滬
等待開盤 01-14 09:30:00 美东时间
1.49
+0.050
+3.47%
華盛通- 最 高1.56
- 今 開1.46
- 成交量 18.90万股
- 最 低 1.44
- 昨 收 1.44
- 總市值 7963.16万
- 52周最高 2.27
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.404
- 委 比 -50.00%
- 總股本 5344.40万
- 歷史最高 117.45
- 量 比 0.82
- 振 幅 8.33%
- 歷史最低 0.404
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ALX Oncology Doses First Patient In Phase 2 ASPEN-09-Breast Trial Evaluating Its Investigational CD47-Inhibitor Evorpacept.
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated
01-08 21:32
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotech company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Jason Lettmann and CMO Barbara Klencke will present on January 15, 2026. The live and replay webcast can be accessed via ALX Oncology’s website. The company’s lead candidate, evorpacept, and ALX2004, an EGFR-targeted antibody-drug conjugate, are currently in clinical tr...
01-08 16:00
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
ALX Oncology announced the first patient dosing in its Phase 2 ASPEN-09-Breast trial evaluating evorpacept, a CD47 inhibitor, in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer patients. The trial aims to assess overall response rates and safety, with interim data expected in Q3 2026. Additionally, the Phase 1 trial for ALX2004, an EGFR-targeted ADC, has initiated the third dose cohort at 4mg/kg, following...
01-08 13:30
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
ALX Oncology announced positive Phase 2 data showing evorpacept combined with R² achieved a 92% complete response rate in untreated indolent non-Hodgkin lymphoma patients, significantly higher than the historical 50% for R² alone. The regimen was well-tolerated, with a 100% overall response rate and promising 1-year survival rates. Further evaluation of minimal residual disease eradication is pending longer follow-up. The study was presented at t...
2025-12-07 13:00
ALX Oncology to Present at Upcoming Investor Conferences
ALX Oncology announced that its leadership will participate in the Jefferies Global Healthcare Conference in London and the Piper Sandler 37th Annual Global Healthcare Conference in New York. The Jefferies event will be on November 19, 2025, at 11:30 AM GMT, and the Piper Sandler event on December 3, 2025, at 9:30 AM EST, both in Fireside Chat format. Webcasts are available on the company's website, and replays will be archived for 90 days. ALX O...
2025-11-18 16:00
ALX Oncology anticipates $2B–$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies
Earnings Call Insights: ALX Oncology Holdings Inc. (ALXO) Q3 2025 Management View CEO Jason Lettmann opened the call by highlighting progress in the evorpacept and ALX2004 clinical programs, emphasizi...
2025-11-08 04:57
ALX Oncology Holdings Q3 Adj. EPS $(0.36) Beats $(0.37) Estimate
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.37) by 1.91 percent. This is a 20 percent increase over losses of $(0.45) per share from
2025-11-07 21:17
Earnings Scheduled For November 7, 2025
Companies Reporting Before The Bell • Kiora Pharmaceuticals (NASDAQ:KPRX) is pr...
2025-11-07 19:11
ALX Oncology Presents Preclinical Data And Trial Design For Ongoing Phase 1 Clinical Trial For ADC Candidate, ALX2004, In Two Poster Presentations At 2025 AACR-NCI-EORTC Conference
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors-Robust body of preclinical data supports ALX2004
2025-10-24 00:31
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
ALX Oncology presented preclinical data and Phase 1 trial design for its novel ADC, ALX2004, targeting EGFR-expressing solid tumors, at the 2025 AACR-NCI-EORTC Conference. ALX2004 demonstrates potent anti-tumor activity and a favorable safety profile, addressing limitations of earlier ADCs. Initial safety data from the first-in-human trial is expected in early 2026. The company highlighted ALX2004's unique design, including a proprietary linker-p...
2025-10-23 16:30
